US-based biopharmaceutical company Regulus Therapeutics has expanded its collaboration with GlaxoSmithKline (GSK), to initiate a Phase ll trial for evaluation of the combination of RG-101 and GSK’s long-acting parenteral (LAP) formulation of GSK2878175, as a potential single-visit cure in patients chronically infected with hepatitis C virus (HCV).
RG-101 is Regulus’ GalNAc-conjugated anti-miR that targets miR-122 to treat chronic hepatitis C virus infection.
Go deeper with GlobalData
The multi-centre, randomised, dose-ranging Phase ll trial will be conducted outside the US, with plans to begin in the fourth quarter of this year.
In the early part of this year, as part of the initial GSK-Regulus clinical trial collaboration agreement, Regulus started enrolling patients in an open-label, Phase II clinical trial combining RG-101 and GSK2878175 to treat HCV.
The trial aims to assess the potential to achieve sustained viral responses post treatment, with a single subcutaneous administration of 4mg/kg of RG-101 in combination with daily oral administrations of 20mg of GSK2878175, for up to 12 weeks in treatment-naïve patients chronically infected with HCV genotypes 1 and 3.
See Also:
Regulus and GSK expect to report interim results from this trial by the end of this year.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataRegulus noted that on the basis of predicted enrollment rates, interim results from the proposed Phase ll trial would be available in the second half of next year, enabling a potential initiation of another trial by the later half of next year.
As part of the initial collaboration, both the firms will equally share the costs associated with the trial.
Regulus Therapeutics president and CEO Dr Paul Grint said: "This is an important next step to advance the scientific understanding of the potential for a combination therapy to achieve a single-visit cure for HCV.
"The market research conducted to date indicates that a potential single visit cure would be a highly preferred product profile to existing regimens."
